New tacrolimus tablet tested in kidney transplant patients
NCT ID NCT04102943
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a tacrolimus tablet (TacroBell) works in people who received a kidney transplant. The goal was to measure drug levels in the blood and see how well patients tolerated it. 128 adults who were getting a kidney from a deceased or living donor took part. The results help doctors understand if this tablet is a good option for preventing organ rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Can your gut bacteria change how transplant drugs work?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors